As consumers adjusted to the "new normal" in the aftermath of the COVID-19 pandemic, dermatologicals showed a robust recovery in 2022, witnessing double-digit growth in retail current value terms. Previously dynamic categories, such as antiparasitic/lice (head and body) treatments, saw demand plummet in 2021 as a consequence of COVID-19 pandemic, which abruptly disrupted school life and children's everyday activities in general. A return to normal schooling and pre-pandemic lifestyles in general...
Euromonitor International's Dermatologicals in Uruguay report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.
Product coverage: Antiparasitics/Lice (Head and Body) Treatments, Antipruritics, Cold Sore Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Dermatologicals, Topical Allergy Remedies/Antihistamines, Topical Antifungals, Topical Germicidals/Antiseptics, Vaginal Antifungals.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Dermatologicals market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market's major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Dermatologicals in Uruguay
Euromonitor International
September 2022
List Of Contents And Tables
DERMATOLOGICALS IN URUGUAY
KEY DATA FINDINGS
2022 DEVELOPMENTS
Robust recovery in 2022 as consumers return to more normal lifestyles
Continuing focus on hygiene sustains demand for topical antifungals
Megalabs remained in top position with a wide portfolio
PROSPECTS AND OPPORTUNITIES
Further recovery expected for dermatological sales
New product development expected to increase added-value choice over the forecast period
Further development of online sales expected, following lockdown expansion
CATEGORY DATA
Table 1 Sales of Dermatologicals by Category: Value 2017-2022
Table 2 Sales of Dermatologicals by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Dermatologicals: % Value 2018-2022
Table 4 LBN Brand Shares of Dermatologicals: % Value 2019-2022
Table 5 Forecast Sales of Dermatologicals by Category: Value 2022-2027
Table 6 Forecast Sales of Dermatologicals by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN URUGUAY
EXECUTIVE SUMMARY
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2017-2022
Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 13 Distribution of Consumer Health by Format: % Value 2017-2022
Table 14 Distribution of Consumer Health by Format and Category: % Value 2022
Table 15 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources
Despite the return of restrictions in early 2022 as cases of COVID-19 once again surged in China, dermatologicals is set to record another positive performance, following high value growth the previous year as local consumers started to spend greater time outside of the home, including exercise, lea...
Topical allergy remedies is set to be the fastest growing dermatologicals category in 2022, as the incidence of allergies is on the rise and consumers have become more and more confident in self-medication. Changes in eating habits and poor food quality are amongst the factors contributing to a grea...
The performance of dermatologicals was not significantly affected by the Coronavirus (COVID-19) pandemic in 2020. This was mainly due to the specific nature of the ailments and conditions dermatologicals are used to relieve. While increased levels of stress and anxiety during the pandemic saw retail...
Whilst medicated shampoo recorded value growth in 2022 due to inflation and price increases, volume sales experienced decline in the year. This drop in sales is attributable to the increase in selling prices in relation to the purchasing power of Tunisian consumers, and as the majority of products a...
Sales in hair loss treatments follow seasonal trends, along with health-related factors. Hair weakens and becomes vulnerable to shedding due to reasons such as seasonality (seasonal transitions), stress, hormonal changes, and thermal applications. Therefore, an increase in sales is seen in the sprin...
The expansion of the dermatologicals category has been mainly driven by the strong growth of medicated shampoos, hair loss treatments and paediatric dermatologicals. The stress related to COVID-19 and, more recently, to high energy and commodity prices has caused multiple scalp problems amongst cons...
Having fallen sharply in 2020, retail constant value sales (2021 prices) of dermatologicals began to recover in 2021, and this trend extended into 2022—albeit with a more modest growth rate. However, retail constant value sales remained well below their pre-pandemic peak.
Euromonitor In...
Demand for antiparasitics/lice (head and body) treatments in Ireland fell sharply over 2020-2021 as schools were closed for lengthy periods and social distancing was widely observed as part of the national effort to curb the spread of COVID-19. With schools having since fully reopened and levels of ...
Dermatologicals is projected to see positive retail volume and current value growth over 2022. All significant categories are set to see high single-digit or double-digit retail current value increments. Antiparasitics/lice (head and body) treatments is expected to see the highest retail volume and ...
Dermatologicals is set to see significantly stronger growth in 2022 compared to 2020 and 2021, in current value terms. During 2020-2021 consumers spent considerably more time at home and thus many dermatological complaints took a back seat, with social distancing and the lack of activity away from t...